<DOC>
	<DOCNO>NCT00030498</DOCNO>
	<brief_summary>Phase I trial study effectiveness erlotinib treat patient metastatic unresectable solid tumor liver kidney dysfunction . Biological therapy erlotinib may interfere growth tumor cell slow growth tumor</brief_summary>
	<brief_title>Erlotinib Treating Patients With Solid Tumors Liver Kidney Dysfunction</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose erlotinib patient solid tumor hepatic renal dysfunction . II . Determine pharmacokinetics drug patient . OUTLINE : This dose-escalation , multicenter study . Patients stratify accord hepatic renal dysfunction ( albumin less 2.5 g/dL , direct bilirubin le 1.0 mg/dL , AST , creatinine normal v direct bilirubin 1.0-7.0 mg/dL , AST , creatinine normal vs creatinine 2.5-5.0 mg/dL , albumin 2.5 g/dL great , AST le 3 time upper limit normal , direct bilirubin le 1.0 mg/dL ) . Patients receive oral erlotinib daily . Treatment continue absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos erlotinib maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , least 6 evaluable patient treat dose .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Laryngeal Diseases</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Laryngeal Neoplasms</mesh_term>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Oropharyngeal Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Verrucous</mesh_term>
	<mesh_term>Carcinoma , Basal Cell</mesh_term>
	<mesh_term>Papilloma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Ependymoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Oligodendroglioma</mesh_term>
	<mesh_term>Salivary Gland Neoplasms</mesh_term>
	<mesh_term>Paranasal Sinus Neoplasms</mesh_term>
	<mesh_term>Granuloma</mesh_term>
	<mesh_term>Carcinoma , Adenoid Cystic</mesh_term>
	<mesh_term>Anus Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Unknown Primary</mesh_term>
	<mesh_term>Breast Neoplasms , Male</mesh_term>
	<mesh_term>Carcinoma , Mucoepidermoid</mesh_term>
	<mesh_term>Esthesioneuroblastoma , Olfactory</mesh_term>
	<mesh_term>Papilloma , Inverted</mesh_term>
	<mesh_term>Glioma , Subependymal</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histologically confirm solid tumor , include glioma follow epithelial malignancy : Nonsmall cell lung Mesothelioma Breast Head neck Esophageal Pancreatic Bladder Prostate Ovarian Anal Colorectal carcinoma Cervical carcinoma Hepatocellular carcinoma Metastatic unresectable disease Standard curative palliative therapy exist longer effective Epidermal growth factor receptor ( EGFR ) positive Hepatic renal dysfunction define one following : Direct bilirubin 1.07.0 mg/dL AST Albumin le 2.5 g/dL Creatinine 2.55.0 mg/dL Brain metastases allow provided patient asymptomatic , previously treat , stable disease least 2 month , currently receive steroid therapy Hormone receptor status : Not specify Male female Performance status ECOG 02 Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 See Disease Characteristics No evidence biliary obstruction See Disease Characteristics No evidence renal obstruction No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia No gastrointestinal tract disease would preclude ability take oral medication No requirement IV alimentation No active peptic ulcer disease No prior corneal abnormality ( e.g. , dry eye syndrome Sjogren 's syndrome ) No prior congenital abnormality ( e.g. , Fuch 's dystrophy ) No prior abnormal slitlamp exam use vital dye ( e.g. , fluorescein BengalRose ) No prior abnormal corneal sensitivity test ( e.g. , Schirmer test similar tear production test ) No concurrent uncontrolled illness No ongoing active infection No psychiatric illness social situation would preclude study compliance Not pregnant nursing Fertile patient must use effective contraception No concurrent filgrastim ( GCSF ) sargramostim ( GMCSF ) At least 4 week since prior chemotherapy ( 6 week melphalan mitomycin ) No prior nitrosoureas See Disease Characteristics No concurrent steroid At least 4 week since prior radiotherapy At least 4 week since prior major surgery No prior surgical procedure affect absorption No prior EGFRtargeting therapy , include gefitinib Imclone C225 At least 3 month since prior suramin More 7 day since prior grapefruit juice More 7 day since prior CYP3A4 inhibitor No concurrent grapefruit juice No concurrent CYP3A4 inducer , substrate , inhibitor No concurrent medication know affect hepatic renal function , include antiseizure medication nonsteroidal antiinflammatory agent No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>